糖尿病精准医学:潜力、陷阱与风险并存,但尚未到常规应用之时
本文为非系统性综述,指出精准医学在苯丙酮尿症、特定类型MODY等单基因病已有成功案例,但2型糖尿病为多基因异质性疾病,现有证据不足以支持将精准医学方法广泛用于其预防和管理的常规临床实践。多数方法看似精准实则不然,过于复杂且过度聚焦血糖预测。
要点
- 单基因病(如苯丙酮尿症特定饮食、特定类型MODY的磺脲类治疗)已有精准医学成功范例。
- 2型糖尿病为多基因、多因素、异质性代谢紊乱,单基因病研究策略难以直接套用。
- 现有证据不足以支持将精准医学方法广泛用于2型糖尿病常规临床实践。
核心结论
- 现有证据不足以支持将精准医学方法广泛用于2型糖尿病的常规临床实践。
- 评估新策略时需保持谦逊与健康怀疑态度,并要求在实施前超越现有证据阈值。
研究设计与样本
- 非系统性综述,聚焦2型糖尿病精准医学预防与管理的证据局限及实施前需克服的挑战。
主要发现
- 多数精准医学方法看似精准实则不然、过于复杂,且过度聚焦于用有限个体特征预测血糖水平,而非关注完整的人及其背景。
- 单基因病(如苯丙酮尿症特定饮食、特定类型MODY的磺脲类治疗)已有成功精准医学范例。
- 2型糖尿病为多基因、多因素、异质性的代谢紊乱集合,单基因病研究策略不太可能为多基因性状带来类似实践变革。
临床怎么用
- 原文未据此给出推荐;作者认为现有证据不足以支持将精准医学方法广泛用于2型糖尿病常规临床实践。
局限性
- 本文为非系统性综述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rapid advances in technology and data science have the potential to improve the precision of preventive and therapeutic interventions, and enable the right treatment to be recommended, at the right time, to the right person. There are well-described examples of successful precision medicine approaches for monogenic conditions such as specific diets for phenylketonuria, and sulfonylurea treatments for certain types of MODY. However, the majority of chronic diseases are polygenic, and it is unlikely that the research strategies used for monogenic diseases will deliver similar changes to practice for polygenic traits. Type 2 diabetes, for example, is a multifactorial, heterogeneous, polygenic palette of metabolic disorders. In this non-systematic review I highlight limitations of the evidence, and the challenges that need to be overcome prior to implementation of precision medicine in the prevention and management of type 2 diabetes. Most precision medicine approaches are spuriously precise, overly complex and too narrowly focused on predicting blood glucose levels with a limited set of characteristics of individuals rather than the whole person and their context. Overall, the evidence to date is insufficient to justify widespread implementation of precision medicine approaches into routine clinical practice for type 2 diabetes. We need to retain a degree of humility and healthy scepticism when evaluating novel strategies, and to demand that existing evidence thresholds are exceeded prior to implementation.
引用
- Griffin S. Diabetes precision medicine: plenty of potential, pitfalls and perils but not yet ready for prime time. Diabetologia. 2022. PMID: 35999379. doi:10.1007/s00125-022-05782-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。